PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.
Location: United States, New Jersey, Paramus
Employees: 51-200
Total raised: $3M
Founded date: 1999
Funding Rounds 1
Date | Series | Amount | Investors |
28.08.2024 | Grant | $3M | - |
Mentions in press and media 4
Date | Title | Description |
29.08.2024 | The Future of AI: Pioneers and Innovations Shaping Tomorrow | In the bustling world of technology, artificial intelligence (AI) stands as a beacon of innovation. Companies like Inverted AI and PsychoGenics are not just participants; they are trailblazers. Their recent strides in AI-driven solutions hi... |
28.08.2024 | PsychoGenics Receives $3M SBIR Grant | PsychoGenics, a Paramus, NJ-based company which specializes in AI-enabled phenotypic drug discovery, received $3M in SBIR Grant by NIMH. The company intends to use the amount to develop eCube®, its proprietary AI-enabled EEG platform, along... |
26.08.2024 | Inverted AI Appoints Dr. Jeff Schneider to Board of Directors | Vancouver, BC | August 26, 2024 – Inverted AI, a leader in AI-driven simulation technologies for autonomous systems, is pleased to announce the appointment of Dr. Jeff Schneider as the newest member of its Board of Directors. This strategic... |
- | PsychoGenics Launches AI Platform to Revolutionize Drug Discovery | What You Should Know: – PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform. The platform supports phenotypic d... |